EUVIMEDEUVIMED entdecken
Crossref

Synergistic cardioprotection by liraglutide and deferoxamine against doxorubicin-induced cardiotoxicity via modulation of ACSL-4/Nrf-2/GPX-4 signaling

Nada Monir, Omneya Galal, Azza S Awad, Hala F Zaki, Mona M Saber

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026

DOI: 10.1007/s00210-026-05646-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Nada Monir und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ahram Canadian University, Giza, Egypt. Hauptthemen laut MEDLINE: Doxorubicin, Deferoxamine, Cardiotoxicity, Liraglutide. Die Arbeit nennt 84 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Doxorubicin (Dox) is a highly effective chemotherapeutic agent whose clinical utility is limited by dose-dependent cardiotoxicity, largely driven by iron overload-dependent cell death (ferroptosis) and excessive reactive oxygen species (ROS). Targeting ferroptosis represents a promising strategy for cardioprotection. This study investigated the cardioprotective potential of liraglutide (Lira), deferoxamine (DFO), and their combination in a rat model of Dox-induced cardiotoxicity. Male Wistar rats received Dox (20 mg/kg, i.p.) following pretreatment with Lira (200 μg/kg/day), DFO (50 mg/kg/week), or their combination for 3 weeks. Cardiac injury markers, iron homeostasis, oxidative stress indices, ferroptosis-related gene expression, and histopathological alterations were evaluated. Dox administration induced marked cardiac dysfunction, elevated CK-MB and troponin-T, disrupted iron regulation, increased lipid peroxidation, suppressed Nrf-2/GPX-4 signaling, and triggered ferroptosis. Both Lira and DFO significantly attenuated these alterations; however, combined therapy produced superior restoration of ventricular function, normalization of iron parameters, enhancement of antioxidant defenses, and preservation of myocardial architecture. These findings demonstrate that simultaneous targeting of iron overload and antioxidant signaling confers enhanced cardioprotection against Dox-induced injury. The Lira-DFO combination may represent a promising adjunct strategy to mitigate anthracycline-associated cardiotoxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinDeferoxamineCardiotoxicityLiraglutideCardiotonic AgentsAnimalsMaleRats, WistarNF-E2-Related Factor 2Signal TransductionRatsDrug SynergismFerroptosisAntibiotics, AntineoplasticOxidative StressIron

Stichwörter der Autor:innen

CardiotoxicityDeferoxamineDoxorubicinFerroptosisLiraglutideNrf-2/GPX-4/HO-1 axis

Substanzen

DoxorubicinDeferoxamineNF-E2-Related Factor 2LiraglutideNfe2l2 protein, ratCardiotonic AgentsAntibiotics, AntineoplasticIron

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ahram Canadian University, Giza, Egypt.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Giza, Egypt.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Giza, Egypt. mona.magdy@pharma.cu.edu.eg.
  • Department of Clinical Pharmacy, Faculty of Pharmacy, E-JUST, Alexandria, Egypt. mona.magdy@pharma.cu.edu.eg.

Zitieren

APA

Monir, N., Galal, O., Awad, A. S., Zaki, H. F., & Saber, M. M. (2026). Synergistic cardioprotection by liraglutide and deferoxamine against doxorubicin-induced cardiotoxicity via modulation of ACSL-4/Nrf-2/GPX-4 signaling. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-05646-6

Vancouver

Monir N, Galal O, Awad AS, Zaki HF, Saber MM. Synergistic cardioprotection by liraglutide and deferoxamine against doxorubicin-induced cardiotoxicity via modulation of ACSL-4/Nrf-2/GPX-4 signaling. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-05646-6

BibTeX
@article{Monir2026,
  author = {Monir, Nada and Galal, Omneya and Awad, Azza S and Zaki, Hala F and Saber, Mona M},
  title = {Synergistic cardioprotection by liraglutide and deferoxamine against doxorubicin-induced cardiotoxicity via modulation of ACSL-4/Nrf-2/GPX-4 signaling},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  doi = {10.1007/s00210-026-05646-6}
}
Kostenlos starten →